Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range
- Written by PR Newswire
![]() |
Highlights
- Clarity recently reported that in its diagnostic Phase 1/2 trial, COBRA, 64Cu-SAR-bisPSMA was found to be safe and highly effective in detecting prostate cancer (PC) lesions in patients with biochemical recurrence (BCR).
- In trial participants where standard of care (SOC) imaging was unable to detect any lesions, up to approximately...








